JO3115B1 - مركبات بيريدازينون واستخدامها كمثبطات daao - Google Patents

مركبات بيريدازينون واستخدامها كمثبطات daao

Info

Publication number
JO3115B1
JO3115B1 JOP/2012/0232A JOP20120232A JO3115B1 JO 3115 B1 JO3115 B1 JO 3115B1 JO P20120232 A JOP20120232 A JO P20120232A JO 3115 B1 JO3115 B1 JO 3115B1
Authority
JO
Jordan
Prior art keywords
pyridazinone compounds
daao inhibitors
daao
inhibitors
compounds
Prior art date
Application number
JOP/2012/0232A
Other languages
English (en)
Inventor
Livermore David
Miller David
Fieldhouse Charlotte
Kerr Catrina
Hazel Katherine
Merchant Kevin
Kinsella Natasha
Farnaby William
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1114399.7A external-priority patent/GB201114399D0/en
Priority claimed from GB201118658A external-priority patent/GB201118658D0/en
Priority claimed from GBGB1203533.3A external-priority patent/GB201203533D0/en
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of JO3115B1 publication Critical patent/JO3115B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

يوفر الاختراع الحالى مركبات الصيغة (I) وأملاحها المقبولة صيدلياً، (I) حيث R1 وR2 تكون كما هى معرفة فى الوصف، عمليات لتحضيرها، تركيبات صيدلية تحتوى عليها واستخدامها فى العلاج.
JOP/2012/0232A 2011-08-22 2012-08-15 مركبات بيريدازينون واستخدامها كمثبطات daao JO3115B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1114399.7A GB201114399D0 (en) 2011-08-22 2011-08-22 Novel compounds
GB201118658A GB201118658D0 (en) 2011-10-27 2011-10-27 Novel compounds
GBGB1203533.3A GB201203533D0 (en) 2012-02-29 2012-02-29 Novel compounds

Publications (1)

Publication Number Publication Date
JO3115B1 true JO3115B1 (ar) 2017-09-20

Family

ID=46758786

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0232A JO3115B1 (ar) 2011-08-22 2012-08-15 مركبات بيريدازينون واستخدامها كمثبطات daao

Country Status (38)

Country Link
US (6) US9290456B2 (ar)
EP (1) EP2748149B9 (ar)
JP (1) JP6022573B2 (ar)
KR (1) KR101961851B1 (ar)
CN (1) CN103748079B (ar)
AP (1) AP2014007512A0 (ar)
AR (2) AR087607A1 (ar)
AU (1) AU2012298335B2 (ar)
BR (1) BR112014003906B1 (ar)
CA (1) CA2846204C (ar)
CL (1) CL2014000395A1 (ar)
CO (1) CO6910197A2 (ar)
CR (1) CR20140133A (ar)
CY (1) CY1117105T1 (ar)
DK (1) DK2748149T5 (ar)
DO (1) DOP2014000036A (ar)
EA (1) EA024956B1 (ar)
EC (1) ECSP14013215A (ar)
ES (1) ES2559631T3 (ar)
GE (1) GEP20156372B (ar)
HR (1) HRP20151310T2 (ar)
HU (1) HUE026691T2 (ar)
IL (1) IL230143A (ar)
JO (1) JO3115B1 (ar)
ME (1) ME02319B (ar)
MX (1) MX2014000783A (ar)
MY (1) MY180618A (ar)
PE (1) PE20141208A1 (ar)
PH (1) PH12014500405A1 (ar)
PL (1) PL2748149T3 (ar)
PT (1) PT2748149E (ar)
RS (1) RS54515B9 (ar)
SI (1) SI2748149T1 (ar)
SM (1) SMT201600023B (ar)
TW (1) TWI546289B (ar)
UY (1) UY34280A (ar)
WO (1) WO2013027000A1 (ar)
ZA (1) ZA201400153B (ar)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6087504B2 (ja) 2008-11-07 2017-03-01 マサチューセッツ インスティテュート オブ テクノロジー アミノアルコールリピドイドおよびその使用
CA2831392C (en) 2011-03-28 2020-04-28 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
KR102272498B1 (ko) 2011-10-27 2021-07-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
AP2014007637A0 (en) 2011-11-15 2014-05-31 Takeda Pharmaceutical Dihydroxy aromatic heterocyclic compound
WO2014025993A1 (en) 2012-08-08 2014-02-13 The Johns Hopkins University Inhibitors of d-amino acid oxidase
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
US9956113B2 (en) 2013-03-12 2018-05-01 The Board Of Trustees Of The Leland Stanford Junior University Method and system for regulating core body temperature
GB201403944D0 (en) * 2014-03-06 2014-04-23 Takeda Pharmaceutical New use
US9868975B2 (en) * 2014-04-30 2018-01-16 Yufeng Jane Tseng Use of known compounds as D-amino acid oxidase inhibitors
WO2016205691A1 (en) 2015-06-19 2016-12-22 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
WO2019043635A1 (en) 2017-09-01 2019-03-07 Richter Gedeon Nyrt. COMPOUNDS INHIBITING THE ACTIVITY OF D-AMINO ACID OXIDASE
US10336724B2 (en) * 2017-10-18 2019-07-02 Syneurx International (Taiwan) Corp. D-amino acid oxidase inhibitors and therapeutic uses thereof
US12403034B2 (en) 2019-01-31 2025-09-02 Flotherm, Inc. Sleeve-based body temperature regulation
CN109725092A (zh) * 2019-03-19 2019-05-07 北京和合医学诊断技术股份有限公司 检测血液中齐拉西酮含量的液相色谱分析方法
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
WO2022187127A1 (en) 2021-03-01 2022-09-09 Takeda Pharmaceutical Company Limited Use of luvadaxistat for the treatment of cognitive impairment

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH636632A5 (de) 1976-10-08 1983-06-15 Ciba Geigy Ag Neues verfahren zur herstellung von schwermetallkomplexen.
LU75958A1 (ar) 1976-10-08 1978-05-16
GB2025416A (en) 1978-07-14 1980-01-23 Pfizer Ltd Mercaptopyridazinethione antifungal agents
GB8421427D0 (en) 1984-08-23 1984-09-26 Smith Kline French Lab Chemical compounds
EG18314A (en) 1985-09-26 1993-02-28 Squibb & Sons Inc Process for preparing of 2-oxo-1((substituted sulfonyl)amino)carbonyl)-azitidines
US4743685A (en) 1985-09-26 1988-05-10 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]carbonyl]azetidines
DK170088A (da) 1987-04-10 1988-10-11 Hoffmann La Roche Acylderivater
WO1989000423A1 (en) 1987-07-09 1989-01-26 Pfizer Inc. 2-amino-5-hydroxy-4-pyrimidones
JPH01202875A (ja) 1988-02-09 1989-08-15 Fujitsu Ltd 超伝導材料構造の製造方法
US5244890A (en) 1988-06-06 1993-09-14 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
CA2020654A1 (en) 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
ES2077183T3 (es) 1990-11-22 1995-11-16 Cerestar Holding Bv Procedimiento para la produccion de chocolate.
EP0544166A3 (en) 1991-11-26 1993-11-03 Hoffmann La Roche Cephalosporinderivatives
GB9219313D0 (en) 1992-09-11 1992-10-28 Kodak Ltd Method of forming a photographic colour image
EP0724573A1 (en) 1993-10-20 1996-08-07 PHARMACIA & UPJOHN COMPANY Pyrimidinones as antiarthritic and anti-inflammatories
CZ289512B6 (cs) 1994-08-24 2002-02-13 Astra Aktiebolag Spiro-azabicyklické sloučeniny pouľitelné při terapii
JPH092534A (ja) 1995-06-16 1997-01-07 Terada Seisakusho:Kk 茶貯蔵容器
JPH0925234A (ja) 1995-07-12 1997-01-28 Wakunaga Pharmaceut Co Ltd 脳疾患改善剤
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
US6525053B1 (en) 1997-08-22 2003-02-25 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
EP1007515A1 (en) 1997-08-22 2000-06-14 Abbott Laboratories Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
ES2262322T3 (es) 1998-06-10 2006-11-16 Meiji Seika Kaisha, Ltd. Tratamiento de la degenaracion espinocereberal y comoposiciones utiles para el tratamiento de degeneracion espinocerebelar.
EP1124804B1 (en) 1998-10-27 2005-08-24 Abbott Laboratories Prostaglandin endoperoxide h synthase biosynthesis inhibitors
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
JP2002028187A (ja) 2000-07-14 2002-01-29 Toto Ltd 車いす
SE0002729D0 (sv) 2000-07-20 2000-07-20 Astrazeneca Ab Novel compound form
EP1351946A2 (en) 2000-09-01 2003-10-15 Icos Corporation Materials and methods to potentiate cancer treatment
CN101486683B (zh) * 2000-09-18 2011-12-21 卫材R&D管理有限公司 哒嗪酮和三嗪酮化合物及其作为药物制剂的用途
TWI287004B (en) 2000-12-28 2007-09-21 Shionogi & Co A pyridone derivative having an affinity effect for cannabinoid 2 type receptor
ES2319876T3 (es) 2001-05-18 2009-05-14 Astrazeneca Ab Derivados de 4 (fenil-piperazinil-metil) benzamida y su uso para el tratamiento de la ansiedad o trastornos gastrointestinales.
SI1397366T1 (sl) 2001-06-01 2007-06-30 Astrazeneca Ab Nov ligand za nikotinske acetilholinske receptorje, koristen v terapiji
AU2002339696A1 (en) 2001-12-03 2003-06-17 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
ES2416304T3 (es) 2002-01-18 2013-07-31 Astellas Pharma Inc. Derivado de 2-acilaminotiazol o sal del mismo
DE60333746D1 (de) 2002-04-18 2010-09-23 Astrazeneca Ab Thienylverbindungen
US7417049B2 (en) 2002-04-18 2008-08-26 Astrazeneca Ab Furyl compounds
EP1499616B1 (en) 2002-04-18 2009-06-17 AstraZeneca AB Heterocyclic compounds
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202598D0 (sv) 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
WO2004094408A1 (en) 2003-04-23 2004-11-04 Pharmacia & Upjohn Company Llc Substituted pyrimidinones and pyrimidinthiones as crf antagonists
JP4768628B2 (ja) 2003-11-19 2011-09-07 アレイ バイオファーマ、インコーポレイテッド Ｍｅｋの二環系阻害剤及びその使用方法
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
MY141255A (en) 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
AU2004312530A1 (en) 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
WO2005094822A1 (en) 2004-03-22 2005-10-13 Eli Lilly And Company Pyridyl derivatives and their use as mglu5 receptor antagonists
WO2006135828A2 (en) 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors
TWI375669B (en) 2006-03-17 2012-11-01 Sumitomo Chemical Co Pyridazinone compound and use thereof
BRPI0713216A2 (pt) * 2006-06-30 2012-12-04 Sepracor Inc inibiadores heterocìclos fundidos da d-aminoácido oxidase
US7579370B2 (en) 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
MX2009007410A (es) 2007-01-18 2009-09-09 Sepracor Inc Inhibidores de d-aminoacido oxidasa.
AR064962A1 (es) 2007-01-22 2009-05-06 Syngenta Participations Ag Derivados de piridazina utiles como fungicidas
EP2586778A3 (en) * 2007-03-15 2013-07-31 Merck Sharp & Dohme Corp. Pyridazinone derivatives useful as glucan synthase inhibitors
CN102964296B (zh) 2007-03-28 2015-03-25 阿普泰克斯科技公司 去铁酮的氟化衍生物
WO2008156607A1 (en) * 2007-06-12 2008-12-24 Neurogen Corporation Substituted pyrimidinones
JP2009002534A (ja) 2007-06-19 2009-01-08 Denso Corp 熱交換器
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
WO2010017418A1 (en) 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2010058314A1 (en) * 2008-11-18 2010-05-27 Pfizer Inc. Hydroxyquinolin-2(1h)-ones and derivatives thereof
ME02337B (me) 2009-02-05 2016-06-20 Takeda Pharmaceuticals Co Jedinjenja piridazinona
US20130065857A1 (en) 2009-10-12 2013-03-14 Baylor College Of Medicine Novel dxr inhibitors for antimicrobial therapy
ES2862931T3 (es) 2010-03-04 2021-10-08 Merck Sharp & Dohme Inhibidores de la catecol O-metil transferasa y su uso en el tratamiento de trastornos psicóticos
RU2572624C2 (ru) 2010-03-04 2016-01-20 Мерк Шарп Энд Домэ Корп. Ингибиторы катехол-о-метилтрансферазы и их применение в лечении психических расстройств
WO2011109261A1 (en) 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
US20120046232A1 (en) 2010-06-22 2012-02-23 Medical University Of South Carolina Compositions and methods for reducing relapse of addictive behavior
CA2840060A1 (en) 2011-06-27 2013-01-03 Kyorin Pharmaceutical Co., Ltd. Bridged bicyclic compounds for the treatment of bacterial infections
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
JP2013051513A (ja) 2011-08-30 2013-03-14 Minebea Co Ltd ダンパー及びそれを用いたスピーカ
AP2014007637A0 (en) 2011-11-15 2014-05-31 Takeda Pharmaceutical Dihydroxy aromatic heterocyclic compound
US8868710B2 (en) 2011-11-18 2014-10-21 Amazon Technologies, Inc. Virtual network interface objects
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
HK1219274A1 (zh) 2013-02-21 2017-03-31 Takeda Pharmaceutical Company Limited 哒嗪酮化合物的制备方法
GB201403944D0 (en) 2014-03-06 2014-04-23 Takeda Pharmaceutical New use
JP5897196B1 (ja) 2015-10-05 2016-03-30 大同化成工業株式会社 糖又は糖アルコール、膨潤型結合剤、崩壊剤及び高吸収性賦形剤を含む複合化造粒物及びその製造方法
EP3354283B1 (en) 2017-06-20 2019-08-07 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical capsule composition comprising silodosin
US10336724B2 (en) 2017-10-18 2019-07-02 Syneurx International (Taiwan) Corp. D-amino acid oxidase inhibitors and therapeutic uses thereof
US12370192B2 (en) 2019-09-16 2025-07-29 Takeda Pharmaceutical Company Limited Azole-fused pyridazin-3(2H)-one derivatives
WO2022187127A1 (en) 2021-03-01 2022-09-09 Takeda Pharmaceutical Company Limited Use of luvadaxistat for the treatment of cognitive impairment

Also Published As

Publication number Publication date
ECSP14013215A (es) 2014-05-31
IL230143A0 (en) 2014-03-06
US20150030704A1 (en) 2015-01-29
TWI546289B (zh) 2016-08-21
KR101961851B1 (ko) 2019-03-26
PE20141208A1 (es) 2014-09-19
AP2014007512A0 (en) 2014-03-31
AU2012298335B2 (en) 2017-06-01
US9290456B2 (en) 2016-03-22
CL2014000395A1 (es) 2014-12-05
EA024956B1 (ru) 2016-11-30
PL2748149T3 (pl) 2016-04-29
WO2013027000A1 (en) 2013-02-28
KR20140054297A (ko) 2014-05-08
US12186313B2 (en) 2025-01-07
MX2014000783A (es) 2014-04-14
ES2559631T9 (es) 2018-03-13
DK2748149T5 (en) 2017-04-24
CA2846204A1 (en) 2013-02-28
EP2748149B9 (en) 2017-11-15
US9931340B2 (en) 2018-04-03
JP2014524461A (ja) 2014-09-22
ES2559631T3 (es) 2016-02-15
DOP2014000036A (es) 2014-06-30
DK2748149T3 (en) 2016-01-25
CN103748079B (zh) 2016-03-16
SI2748149T1 (sl) 2016-02-29
RS54515B1 (en) 2016-06-30
MY180618A (en) 2020-12-03
US20220008416A1 (en) 2022-01-13
CO6910197A2 (es) 2014-03-31
SMT201600023B (it) 2016-02-25
HRP20151310T1 (xx) 2016-01-01
UY34280A (es) 2012-10-31
TW201313687A (zh) 2013-04-01
JP6022573B2 (ja) 2016-11-09
US20130052281A1 (en) 2013-02-28
CR20140133A (es) 2014-06-05
GEP20156372B (en) 2015-09-25
IL230143A (en) 2017-03-30
HUE026691T2 (hu) 2016-07-28
US11129828B2 (en) 2021-09-28
PT2748149E (pt) 2016-02-04
EP2748149A1 (en) 2014-07-02
EP2748149B1 (en) 2015-10-21
CA2846204C (en) 2021-04-27
CY1117105T1 (el) 2017-04-05
AU2012298335A1 (en) 2014-01-30
RS54515B9 (sr) 2020-12-31
HK1194072A1 (en) 2014-10-10
CN103748079A (zh) 2014-04-23
US20200121678A1 (en) 2020-04-23
NZ620239A (en) 2015-10-30
BR112014003906A2 (pt) 2017-03-14
AR087607A1 (es) 2014-04-03
AR127309A2 (es) 2024-01-10
HRP20151310T2 (hr) 2018-03-23
BR112014003906B1 (pt) 2022-03-22
US20180177780A1 (en) 2018-06-28
EA201490471A1 (ru) 2014-05-30
ME02319B (me) 2016-06-20
PH12014500405A1 (en) 2014-04-07
US10463663B2 (en) 2019-11-05
US20170173007A1 (en) 2017-06-22
ZA201400153B (en) 2015-12-23

Similar Documents

Publication Publication Date Title
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
PH12017502141A1 (en) Compounds and their methods of use
MY199894A (en) Prmt5 inhibitors and uses thereof
IN2014MN02598A (ar)
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
IN2014CN04530A (ar)
UA109010C2 (en) Morpholino pyrividines and their use in therapy
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
PH12014500199A1 (en) Indazoles
PH12015500260A1 (en) Neprilysin inhibitors
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MY175854A (en) Novel quinolone derivatives
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
WO2013004995A8 (en) Pyrimidinone compounds and their use
MX340300B (es) Compuestos de cromenona como inhibidores de pi 3-quinasa para el tratamiento del cancer.
GB201209587D0 (en) Therapeutic compounds
IN2015DN01119A (ar)
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
TW201613864A (en) Novel compounds
MX340574B (es) Imidazo pirazinas.
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
MX348127B (es) Derivados de quinazolinona como inhibidores del virus de la hepatitis c.
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors
UA111851C2 (uk) Сполуки піридазинону та їх використання як інгібіторів daao
NZ747821A (en) Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof